Payment overview · 2025
General Payments
$1,627.55
85 reported records · 28 companies
Healthcare provider profile · identity verified
Abra Ann Woolard, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ST. JOSEPH, MO · NPI 1194067991
Verified facts
What the public records show
CMS Open Payments records show Abra Ann Woolard, APRN received $1,627.55 in general payments during 2025 across 85 reported records.
ABBVIE INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Nuplazid, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Qulipta by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nuplazid by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ampyra by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $340.05 | 20.9% | 29 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $189.49 | 11.6% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$154.88 | 9.5% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $87.71 | 5.4% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $83.99 | 5.2% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $71.68 | 4.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.65 | 3.7% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$49.46 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.00 | 3.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $48.17 | 3.0% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $45.19 | 2.8% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $43.34 | 2.7% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $43.21 | 2.6% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $41.59 | 2.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.56 | 2.5% | 2 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $33.09 | 2.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.08 | 1.7% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $24.50 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.31 | 1.5% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.60 | 1.4% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.91 | 1.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.40 | 1.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.84 | 1.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.49 | 1.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.27 | 1.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.19 | 1.1% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $16.61 | 1.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16.29 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,627.55 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $196.82 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $174.18 | 16 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $154.88 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $87.71 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $84.73 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $71.68 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $59.65 | 4 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $58.50 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $50.96 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $49.46 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $49.00 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $48.17 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $45.19 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $41.59 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $41.56 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Topiramate | Topiramate | 404 | 63 |
| Levetiracetam | Levetiracetam | 391 | 62 |
| Donepezil Hcl | Donepezil Hcl | 375 | 76 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 298 | 47 |
| Gabapentin | Gabapentin | 262 | 55 |
| Memantine Hcl | Memantine Hcl | 233 | 62 |
| Baclofen | Baclofen | 177 | 39 |
| Lamotrigine | Lamotrigine | 174 | 21 |
| Primidone | Primidone | 149 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 123 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 17 |
| Propranolol Hcl | Propranolol Hcl | 86 | 17 |
| Entacapone | Entacapone | 81 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 81 | 21 |
| Rizatriptan | Rizatriptan Benzoate | 68 | 14 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 57 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 57 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 49 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Amantadine | Amantadine Hcl | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | suppressed |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 39 | suppressed |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 32 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 19 | suppressed |
| Austedo Xr | Deutetrabenazine | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Ampyra | Dalfampridine | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,627.55 · 85 records | ABBVIE INC. | AUSTEDO XR, BOTOX, BRIUMVI, EPIDIOLEX, Fintepla, Gocovri, INFINITY, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, ONGENTYS, Ocrevus Zunovo, PERCEPT PC BRAINSENSE, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, Tascenso ODT, UBRELVY, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYALEV, VYEPTI, VYVGART HYTRULO, XYWAV, Xeomin, ZEPOSIA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error